Clinical workflow features being implemented by Flatiron will help address both coordination of care and physician burnout, explained Amila Patel, PharmD, BCOP, technical lead, Clinical Oncology, Flatiron Health.
Clinical workflow features being implemented by Flatiron will help address both coordination of care and physician burnout, explained Amila Patel, PharmD, BCOP, technical lead, Clinical Oncology, Flatiron Health.
Transcript
How will new features in the clinical workflow help promote better coordination of care?
Collectively, that’s exactly what we’ve been aiming to do with these features. So, our visit note experience enables collaboration between the care team together by introducing real-time collaboration and auto-saving functionality. Our inbox experience is intended to be such that people are coordinating care across the care team and we’re looking to make sure this information reaches the patient and that there’s care collaboration with them.
Will these new features also impact the growing issue of physician burnout?
Yes, everything we do in in that mind set of reducing physician burnout. As a specific example, with our Flatiron Assist tool, we’re trying to make it such that providers can go directly to the regimen they know while also proving concordance with the [National Comprehensive Cancer Center] guidelines and hopefully streamlining the prior authorization process, which we know is just so burdensome for both providers and patients.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More